维得利珠单抗联合硫嘌呤与维得利珠单抗单药治疗克罗恩病相比降低治疗失败风险
基于美国和法国全国医疗数据库模拟目标试验,比较维得利珠单抗联合硫嘌呤与单药治疗在克罗恩病和溃疡性结肠炎中的有效性。倾向评分匹配后,克罗恩病联合治疗组第26周治疗失败风险降低(RR 0.85,95% CI 0.74-0.98),溃疡性结肠炎组风险降低程度较小且未达统计学显著(RR 0.90,95% CI 0.77-1.05)。
要点
- 克罗恩病联合治疗组第26周治疗失败236例(29.3%),单药组376例(34.3%),RR 0.85。
- 溃疡性结肠炎联合治疗组第16周治疗失败236例(21.7%),单药组263例(24.2%),RR 0.90。
- 克罗恩病联合治疗降低治疗失败风险,溃疡性结肠炎未达统计学显著。
核心结论
- 在美国和法国数据库中,维得利珠单抗联合硫嘌呤与维得利珠单抗单药相比,克罗恩病治疗失败风险降低,溃疡性结肠炎未达统计学显著。
研究设计与样本
- 基于两个美国和一个法国全国医疗数据库模拟目标试验,纳入启动维得利珠单抗的克罗恩病和溃疡性结肠炎患者。
- 研究方法包括混杂调整和结局定义,已在SONIC和SUCCESS试验的成功模拟中得到验证。
- 共10 299例维得利珠单抗使用者,经1:1倾向评分匹配后,克罗恩病804对、溃疡性结肠炎1088对联合治疗与单药治疗患者。
主要发现
- 克罗恩病联合治疗组第26周治疗失败236例(29.3%),单药组376例(34.3%)。
- 溃疡性结肠炎联合治疗组第16周治疗失败236例(21.7%),单药组263例(24.2%)。
- 克罗恩病联合治疗较单药治疗治疗失败风险降低(RR 0.85,95% CI 0.74-0.98)。
- 溃疡性结肠炎联合治疗较单药治疗治疗失败风险降低程度较小,未达统计学显著(RR 0.90,95% CI 0.77-1.05)。
- 各数据库结果一致。
关键数值与推荐
- 治疗失败定义为因疾病活动住院或手术、治疗转换或长期使用糖皮质激素。
- 克罗恩病RR 0.85(95% CI 0.74-0.98),溃疡性结肠炎RR 0.90(95% CI 0.77-1.05)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: While infliximab combined to thiopurines is more effective than infliximab monotherapy in patients with Crohn's disease (CD) and UC, the impact of adding thiopurines to vedolizumab remains controversial. We emulated two target trials comparing the effectiveness of combination therapy versus vedolizumab monotherapy in CD and UC. DESIGN: Based on two US and the French nationwide healthcare databases, patients with CD and UC who initiated vedolizumab were identified. The study methodology, including confounding adjustment and outcome definitions, were previously validated in successful emulations of the SONIC and SUCCESS trials. Risk ratios for treatment failure based on hospitalisation or surgery related to disease activity, treatment switch, or prolonged corticosteroids use, were estimated after 1:1 propensity score (PS) matching. RESULTS: Among a total of 10 299 vedolizumab users, 804 CD and 1088 UC pairs of combination therapy versus vedolizumab monotherapy users were PS matched. Treatment failure occurred at week 26 in 236 (29.3%) and 376 (34.3%) patients with CD and at week 16 in 236 (21.7%) and 263 (24.2%) patients with UC initiating combination therapy and vedolizumab monotherapy, respectively. The risk of treatment failure was decreased with combination therapy compared with vedolizumab monotherapy in CD (RR 0.85, 95% CI: 0.74 to 0.98) and to a lesser extent in UC (RR 0.90, 95% CI: 0.77 to 1.05). Findings were consistent across databases. CONCLUSION: Using validated methodologies, combination therapy with vedolizumab and thiopurines was associated with lower treatment failure compared with vedolizumab monotherapy in CD but not UC across the USA and France.
引用
- Kirchgesner J, Desai RJ, Schneeweiss MC, et al. Decreased risk of treatment failure with vedolizumab and thiopurines combined compared with vedolizumab monotherapy in Crohn's disease. Gut. 2022. PMID: 35387877. doi:10.1136/gutjnl-2022-327002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。